Published in Arteriosclerosis on December 12, 1986
Lipid lowering drugs. BMJ (1990) 1.17
High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome. Pharmacogenomics J (2010) 0.85
Clinical experience with simvastatin compared with cholestyramine. Drugs (1988) 0.79
Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study. Pharmacogenet Genomics (2012) 0.78
Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome. Springerplus (2014) 0.76
Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation (1999) 8.04
Community education for cardiovascular health. Lancet (1977) 6.32
Assessment of habitual physical activity by a seven-day recall in a community survey and controlled experiments. Am J Epidemiol (1985) 6.10
Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia (2003) 5.91
Variation in office-based quality. A claims-based profile of care provided to Medicare patients with diabetes. JAMA (1995) 5.86
Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation (1999) 5.62
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med (1999) 5.09
The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med (1993) 4.61
Experience with human growth hormone in Great Britain: the report of the MRC Working Party. Clin Endocrinol (Oxf) (1979) 4.42
The community-based strategy to prevent coronary heart disease: conclusions from the ten years of the North Karelia project. Annu Rev Public Health (1985) 4.30
The Stanford Five-City Project: design and methods. Am J Epidemiol (1985) 4.06
Identification of in-hospital complications from claims data. Is it valid? Med Care (2000) 3.92
Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest (1995) 3.44
Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA (1994) 3.30
Use of administrative data to find substandard care: validation of the complications screening program. Med Care (2000) 3.26
Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation (1998) 3.18
Serum cholesterol. Doing the right thing. Circulation (1993) 3.16
Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med (2000) 3.14
The community-based model of life style intervention trials. Am J Epidemiol (1978) 3.12
Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem (1990) 3.04
Studies of the proteins in human plasma very low density lipoproteins. J Biol Chem (1969) 2.98
Cholesterol and coronary heart disease. A new era. JAMA (1986) 2.95
Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation (2001) 2.93
Indirect measures of cigarette use: expired-air carbon monoxide versus plasma thiocyanate. Prev Med (1984) 2.91
Risk factors for the development of cholelithiasis in man (second of two parts). N Engl J Med (1978) 2.78
Does clinical evidence support ICD-9-CM diagnosis coding of complications? Med Care (2000) 2.74
Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest (1970) 2.68
Drug treatment of dyslipidemias: practical guidelines for the primary care physician. Heart Dis Stroke (1994) 2.68
Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci U S A (1989) 2.68
Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. J Clin Invest (1975) 2.65
Reducing the risk of cardiovascular disease: effects of a community-based campaign on knowledge and behavior. J Community Health (1977) 2.64
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation (2001) 2.60
A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A (1997) 2.53
Agreement between physicians' office records and Medicare Part B claims data. Health Care Financ Rev (1995) 2.47
Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med (1984) 2.44
Prevalence of severe growth hormone deficiency. Br Med J (1977) 2.43
Should a low-fat, high-carbohydrate diet be recommended for everyone? Beyond low-fat diets. N Engl J Med (1997) 2.43
A school of community paediatrics. Med Educ (1978) 2.42
Effect of dietary stearic acid on plasma cholesterol and lipoprotein levels. N Engl J Med (1988) 2.37
Community intervention trials: reflections on the Stanford Five-City Project Experience. Am J Epidemiol (1995) 2.32
Excess body weight. An underrecognized contributor to high blood cholesterol levels in white American men. Arch Intern Med (1993) 2.32
Hypercholesterolemia in elderly persons: resolving the treatment dilemma. Ann Intern Med (1990) 2.28
Relationship between generalized and upper body obesity to insulin resistance in Asian Indian men. J Clin Endocrinol Metab (1999) 2.25
Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia (2005) 2.23
Rationale of the diet-heart statement of the American Heart Association. Report of Nutrition Committee. Circulation (1982) 2.21
Moderate caffeine use and the risk of spontaneous abortion and intrauterine growth retardation. JAMA (1993) 2.20
Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease. J Clin Invest (1995) 2.20
Effects of obesity and caloric intake on biliary lipid metabolism in man. J Clin Invest (1975) 2.17
AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: executive summary. American Heart Association. Circulation (2000) 2.16
Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med (1971) 2.15
Metabolism of beta-sitosterol in man. J Clin Invest (1970) 2.15
Estimation of adipose tissue mass by magnetic resonance imaging: validation against dissection in human cadavers. J Lipid Res (1994) 2.11
Comparison of effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on plasma lipids and lipoproteins in man. J Lipid Res (1985) 2.11
Measurements of cholesterol turnover, synthesis, and absorption in man, carried out by isotope kinetic and sterol balance methods. J Lipid Res (1969) 2.09
Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun (1972) 2.06
Individual and institutional variables which may serve as indicators of quality of medical care. Med Care (1979) 2.04
The impact of public cholesterol screening on diet, general well-being, and physician referral. Am J Prev Med (1992) 2.04
Mechanisms of lithogenic bile formation in American Indian women with cholesterol gallstones. J Clin Invest (1972) 2.01
Role of insulin in endogenous hypertriglyceridemia. J Clin Invest (1967) 2.00
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol (1997) 1.98
Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole. N Engl J Med (1967) 1.97
Bile acids, liver injury, and liver disease. Arch Intern Med (1972) 1.97
Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest (1986) 1.96
Risk factors for the development of cholelithiasis in man (first of two parts). N Engl J Med (1978) 1.94
Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci U S A (1987) 1.93
Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. J Clin Invest (1974) 1.92
AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol (1999) 1.92
The cost-effectiveness of three smoking cessation programs. Am J Public Health (1987) 1.91
Dietary guidelines for healthy American adults. A statement for health professionals from the Nutrition Committee, American Heart Association. Circulation (1996) 1.91
Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res (1990) 1.90
Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci U S A (1983) 1.89
Isolation and characterisation of an unusual collagen from hyaline cartilage and intervertebral disc. FEBS Lett (1981) 1.89
Affluence and cardiovascular risk factors in Mexican-Americans and other whites in three northern California communities. J Chronic Dis (1975) 1.89
Pancreatic islet-cell antibodies in diabetes mellitus correlated with the duration and type of diabetes, coexistent autoimmune disease, and HLA type. Diabetes (1977) 1.88
Prediction of total subcutaneous abdominal, intraperitoneal, and retroperitoneal adipose tissue masses in men by a single axial magnetic resonance imaging slice. Am J Clin Nutr (1997) 1.86
Influence of diagnostic criteria on the incidence of gestational diabetes and perinatal morbidity. JAMA (1993) 1.86
Protocols for physician assistants. Management of diabetes and hypertension. N Engl J Med (1974) 1.85
Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med (1974) 1.84
Kinetics of triglyceride turnover of very low density lipoproteins of human plasma. J Clin Invest (1965) 1.83
Metabolic studies in familial hypercholesterolemia. Evidence for a gene-dosage effect in vivo. J Clin Invest (1979) 1.82
Dietary beta-sitosterol as an internal standard to correct for cholesterol losses in sterol balance studies. J Lipid Res (1968) 1.76
Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol. N Engl J Med (1986) 1.75
Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development--Diabetes in Early Pregnancy Study. Am J Obstet Gynecol (1991) 1.75
The MRFIT behavior pattern study. II. Type A behavior and incidence of coronary heart disease. Am J Epidemiol (1985) 1.74
A physiological method for estimation of hepatic secretion of biliary lipids in man. Gastroenterology (1972) 1.73
Does the Complications Screening Program flag cases with process of care problems? Using explicit criteria to judge processes. Int J Qual Health Care (1999) 1.71
Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA (1999) 1.70
American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation (2000) 1.69
Use of 100 units/ml insulin in treatment of diabetic children. Arch Dis Child (1976) 1.69
Increased exercise level and plasma lipoprotein concentrations: a one-year, randomized, controlled study in sedentary, middle-aged men. Metabolism (1983) 1.69
The distribution of plasma lipoproteins in middle-aged male runners. Metabolism (1976) 1.69
Comparison of effects of lauric acid and palmitic acid on plasma lipids and lipoproteins. Am J Clin Nutr (1992) 1.67
Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA (1990) 1.65